Cevipabulin

Cevipabulin (TTI-237) is an oral, microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line[1][2].

Product Specifications

CAS Number

[849550-05-6]

Product Name Alternative

TTI-237

UNSPSC

12352005

Hazard Statement

H302

Target

Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Cevipabulin.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@@]([H])(C(F)(F)F)NC1=C(C2=C(F)C=C(OCCCNC)C=C2F)C(Cl)=NC3=NC=NN13

Molecular Formula

C18H18ClF5N6O

Molecular Weight

464.82

Precautions

H302

References & Citations

[1]Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68 (7) :2292-300.|[2]Beyer CF, et al. The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties. Cancer Chemother Pharmacol. 2009 Sep;64 (4) :681-9.